Navigation Links
Sequenom Announces Publication Acceptance of Manuscript From Trisomy 21 R&D Verification Study
Date:12/15/2010

SAN DIEGO, Dec. 15, 2010 /PRNewswire/ -- Sequenom, Inc. (Nasdaq: SQNM) today announced the acceptance of a manuscript describing results from the R&D "locked-assay" verification study conducted by the company's wholly-owned subsidiary, Sequenom Center for Molecular Medicine.

(Logo:  http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)

Details of this study entitled "Noninvasive Detection of Fetal Trisomy 21 by Plasma DNA Sequencing in a Clinical Setting" have been embargoed until publication in the American Journal of Obstetrics and Gynecology.

About Sequenom Center for Molecular Medicine

Sequenom Center for Molecular Medicine (Sequenom CMM®) is a CAP accredited and CLIA-certified specialty reference laboratory dedicated to the development and commercialization of laboratory-developed genetic testing services for prenatal and eye conditions. Utilizing innovative proprietary technologies, Sequenom CMM provides genetic testing results services upon orders from physicians. Working closely with key opinion leaders and experts in obstetrics, retinal care and genetics, Sequenom CMM scientists use a variety of sophisticated and cutting-edge methodologies in the development and validation of laboratory tests. Sequenom CMM is changing the landscape in genetic diagnostics. Visit http://www.scmmlab.com for more information on laboratory services.

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.

SEQUENOM® and Sequenom CMM® are trademarks of Sequenom, Inc.

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the Company's development and commercialization of laboratory-developed genetic testing services for prenatal and eye conditions and its commitment to improving healthcare, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with the Company's ability to develop and commercialize new technologies and products, particularly new technologies such as genetic analysis platforms, noninvasive prenatal diagnostics and laboratory developed tests, reliance upon the collaborative efforts of other parties, the Company's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, government regulation particularly with respect to diagnostic products and laboratory developed tests, obtaining or maintaining regulatory approvals, ongoing litigation and investigations and other risks detailed from time to time in the Company's most recent Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.


'/>"/>
SOURCE Sequenom, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Webcast Alert: Sequenom: Defining the Future of Noninvasive Prenatal Diagnostics
2. SEQUENOM to Hold First Quarter 2009 Financial Results Conference Call on April 30
3. SEQUENOM Announces Launch of MassARRAY Compact 96 System
4. SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights
5. Sequenom Appoints Two New Board Members
6. SEQUENOM Announces Partnership With GeneWorks for Sales & Marketing of MassARRAY Systems and Applications in Australia
7. Sequenom to Present at Two Financial Conferences in March
8. Sequenom to Present at Two Financial Conferences in September
9. Sequenom Announces Formation of Ophthalmology Clinical Advisory Board
10. Sequenom Announces Exercise in Full of Underwriters Option to Purchase Additional Shares
11. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Intelligent Implant Systems announced today that the ... for sale in the United States. These components expand the capabilities of the ... one-level sales beginning in October of 2015, the company has seen significant sales growth ...
(Date:4/28/2016)... PUNE, India , April 28, 2016 ... PT, JT, Stirling, and Brayton Cryocoolers), Service (Technical Support, ... Application, and Geography - Global Forecast to 2022", published ... to USD 2.94 Billion by 2022, at a CAGR ... Browse 70 market data Tables and 94 Figures spread ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... Connecticut's innovative, growing companies, today announced the launch of VentureClash , a ... companies. , “VentureClash looks to attract the best early-stage companies here ...
(Date:4/28/2016)... York, NY (PRWEB) , ... April 28, 2016 ... ... QuickSTAT has made significant investments in recruiting top industry experts, and expanding its ... Platform, which provides industry-leading tools for clients to manage their clinical trial projects. ...
Breaking Biology Technology:
(Date:3/17/2016)... , March 17, 2016 ABI Research, ... forecasts the global biometrics market will reach more ... 118% increase from 2015. Consumer electronics, particularly smartphones, ... fingerprint sensors anticipated to reach two billion shipments ... Dimitrios Pavlakis , Research Analyst at ABI ...
(Date:3/14/2016)... March 14, 2016 http://www.apimages.com ... --> - Renvoi : image disponible via ... --> --> DERMALOG, le ... de nouveaux lecteurs d,empreintes digitales pour l,enregistrement des ... sera utilisé pour produire des cartes d,identité aux ...
(Date:3/10/2016)... March 10, 2016   Unisys Corporation (NYSE: ... Protection (CBP) is testing its biometric identity solution at ... to help identify certain non-U.S. citizens leaving the ... test, designed to help determine the efficiency and accuracy of ... February and will run until May 2016. --> ...
Breaking Biology News(10 mins):